EHA 2021 Highlights Podcast

 

In this episode, Medicom’s correspondent covers 5 presentations from the European Haematology Association (EHA), held 9-17 June 2021. The topics discussed are:

1. 
   
   1. ELEVATE-TN 4-year follow-up: Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia.
   2. Immuno-oncology agents effective in treating classic Hodgkin's lymphoma.
   3. GLOW trial: Fixed-duration ibrutinib + venetoclax was a superior treatment in older or unfit patients with chronic lymphocytic leukaemia compared with chlorambucil + obinutuzumab. These data support the positive clinical profile of all-oral, once-daily, fixed-duration ibrutinib plus venetoclax as first-line treatment for this patient population.
   4. In patients with newly diagnosed multiple myeloma, daratumumab with standard-of-care (i.e. lenalidomide and dexamethasone) achieved superior outcomes in OS, PFS and ORR compared with standard of care alone, as demonstrated by the interim overall survival results of the phase 3 MAIA trial.
   5. The phase 2 BEYOND study demonstrated the safety and efficacy of luspatercept in patients with non-transfusion-dependent β-thalassaemia.

 



Posted on 1 July 202127 June 2024